Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Generics UK

- PMLiVE

Pay-for-delay deals ‘sometimes violate antitrust law’

US Supreme Court rules on deals between pharma and generic drug companies

- PMLiVE

Pay-for-delay deals lead to inflated drug prices says study

Based on analysis of delayed market entry of generic Adderall XR in US

Teva and Sun pay dearly for ‘at-risk’ generic Protonix launch

Will pay $2.15bn in landmark patent infringement lawsuit

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

New vortioxetine studies reinforce efficacy in depression

Supports marketing applications from Takeda and Lundbeck

- PMLiVE

Lundbeck’s Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

- PMLiVE

Global biosimilars market to reach $2.45bn in 2013

And EMA plans to revise its guidelines for the area

- PMLiVE

Lundbeck launches alcohol drug Selincro in Europe

Norway, Finland, Poland and the Baltic countries chosen as first markets

- PMLiVE

GSK accused of delaying generic Seroxat in UK

Could be fined 10 per cent of global turnover if found to have infringed competition law

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links